System Xc- inhibition blocks bone marrow-multiple myeloma exosomal crosstalk, thereby countering bortezomib resistance.
暂无分享,去创建一个
Fang Wang | A. Massie | Rong Fan | K. Vanderkerken | E. Menu | E. De Bruyne | K. De Veirman | P. Vlummens | C. Tu | Yanmeng Wang | A. Maes | I. Oudaert | A. Van der Vreken | Peng Shang
[1] Shota Yamamoto,et al. Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy , 2021, International journal of molecular sciences.
[2] V. Gebski,et al. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition , 2020, Cancer Research.
[3] M. Ratajczak,et al. Extracellular microvesicles/exosomes: discovery, disbelief, acceptance, and the future? , 2020, Leukemia.
[4] Peng Huang,et al. xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.
[5] Y. Zhu,et al. Bone cancer-induced pain is associated with glutamate signalling in peripheral sensory neurons , 2020, Molecular pain.
[6] Raghu Kalluri,et al. The biology, function, and biomedical applications of exosomes , 2020, Science.
[7] Gulden Camci-Unal,et al. Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling , 2019, Leukemia.
[8] Clotilde Théry,et al. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication , 2019, Nature Cell Biology.
[9] R. Schots,et al. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts , 2018, Blood Cancer Journal.
[10] James M. Lee,et al. Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance , 2018, Clinical & translational immunology.
[11] J. Norman,et al. Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells , 2017, Nature Communications.
[12] Yuan-Guo Zhou,et al. Homeostasis of the Intraparenchymal-Blood Glutamate Concentration Gradient: Maintenance, Imbalance, and Regulation , 2017, Front. Mol. Neurosci..
[13] B. Wall,et al. Metabotropic glutamate receptors in cancer , 2017, Neuropharmacology.
[14] B. Frey,et al. Behavioural Effects of Using Sulfasalazine to Inhibit Glutamate Released by Cancer Cells: A Novel target for Cancer-Induced Depression , 2017, Scientific Reports.
[15] C. Mancini,et al. Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target. , 2016, Blood.
[16] P. Mantyh,et al. The cystine/glutamate antiporter system xc− drives breast tumor cell glutamate release and cancer-induced bone pain , 2016, Pain.
[17] X. Leleu,et al. Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity. , 2016, Cancer letters.
[18] A. Sundan,et al. Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells , 2016, Blood Cancer Journal.
[19] D. Ribatti,et al. Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression , 2016, The Journal of pathology.
[20] R. Schots,et al. Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma , 2016, Oncotarget.
[21] K. Vanderkerken,et al. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells , 2015, Oncotarget.
[22] G. Görgün,et al. Targeting the bone marrow microenvironment in multiple myeloma , 2015, Immunological reviews.
[23] O. De Wever,et al. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. , 2014, Blood.
[24] B. Blot,et al. Exosomes secreted by cortical neurons upon glutamatergic synapse activation specifically interact with neurons , 2014, Journal of extracellular vesicles.
[25] H. Sontheimer,et al. Sulfasalazine for brain cancer fits , 2012, Expert opinion on investigational drugs.
[26] A. Palumbo,et al. Multiple myeloma. , 2011, The New England journal of medicine.
[27] P. Conn,et al. Metabotropic glutamate receptors: physiology, pharmacology, and disease. , 2010, Annual review of pharmacology and toxicology.
[28] Miguel C. Seabra,et al. Rab27a and Rab27b control different steps of the exosome secretion pathway , 2010, Nature Cell Biology.
[29] M. B. Mestre,et al. TI-VAMP/VAMP7 and VAMP3/cellubrevin: two v-SNARE proteins involved in specific steps of the autophagy/multivesicular body pathways. , 2009, Biochimica et biophysica acta.
[30] H. Sontheimer,et al. Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor‐κB , 2009, Journal of neurochemistry.
[31] W. Rzeski,et al. Expression of glutamate receptor subunits in human cancers , 2009, Histochemistry and Cell Biology.
[32] Satoru Takahashi,et al. Redox Imbalance in Cystine/Glutamate Transporter-deficient Mice* , 2005, Journal of Biological Chemistry.
[33] J. Howl,et al. Group III metabotropic glutamate receptor activation inhibits Ca2+ influx and nitric oxide synthase activity in bone marrow stromal cells , 2005, Journal of cellular physiology.
[34] Richard Pazdur,et al. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. , 2003, The oncologist.
[35] K. Thielemans,et al. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. , 1997, British Journal of Cancer.